Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

• Status: Completed
• Trial end date: 2017-07-13
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Because this is a product registry study, it will include adult CML patients in any phase treated with dasatinib in China if they meet the following criteria:

• Willing and able to provide written informed consent

• ≥18 years of age

• Confirmed diagnosis of CML patients by attending physician

• Naive to dasatinib before enrollment in study treatment or have received <3 months of dasatinib treatment

• Plan to or are receiving dasatinib therapy based on physician's clinical judgment

• Administered dasatinib after imatinib-resistance or intolerance

Exclusion Criteria:

• Patients participating in clinical trials for CML that explicitly prohibit recruitment in additional studies